Novartis Commits to Global Rollout of Salesforce’s Agentforce 360, Bolstering Bullish Analyst Calls

Overview

• Salesforce said Novartis selected Agentforce Life Sciences and will deploy Agentforce 360 for Life Sciences worldwide over five years, expanding on existing use of Agentforce Health, Data/360, MuleSoft, and marketing products to unify engagement across commercial and patient-facing teams.
• BTIG initiated Salesforce with a Buy and a $335 target on December 17, while Mizuho reiterated a Buy with a $340 target in mid-December, citing progress in commercializing Agentforce.
• A new roundup highlighted improving valuation metrics and reported that Agentforce and Data Cloud ARR grew 330% year over year in the third quarter, with Barron’s and BTIG arguing investors are overly discounting Salesforce’s outlook.
• Jim Cramer noted investor concern that AI tools could enable customers to build more in-house software but maintained a positive stance on Salesforce at roughly 20 times next year’s earnings, pointing out the stock closed up $4.72 on the day he commented.
• Cramer has also touted Agentforce’s reported roughly $500 million run rate and cited Costco and CVS as users, while emphasizing that continued performance from the agentic platform remains the key proof point.